HCPCS Level II code J7320 represents a single 1 mg unit of hyaluronan derivative (GenVisc 850) formulated for intra-articular injection, a viscosupplementation therapy used to manage joint pain. Nationally, this code is relevant for outpatient musculoskeletal care, orthopedics, rheumatology, and pain management settings where intra-articular injections are administered. The code matters because it indexes a specific product and unit size, informing billing, utilization tracking, and coverage determinations across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical indication and typical site of service, payer coverage considerations and common billing modifiers, and benchmarking context where available. The publication summarizes reimbursement benchmarks, common administrative issues when billing for viscosupplementation, and implications for coding accuracy.

This piece provides clinicians, billing staff, and policy analysts with a concise reference to HCPCS Level II code J7320, clarifying its clinical role, administrative considerations, and where to look for payer-specific policies and coverage rules. Data not available in the input is noted where applicable.